Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.
Therapy Area
ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM
GRI Bio’s tazarotene achieves Phase IIa IPF success
Roche posts second Phase III win for oral SERD
New HBV vaccine guidance likely to increase infection among newborns
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Belite eyes tinlarebant approval after late-stage Stargardt success
